This is a preview of subscription content, log in via an institution to check access.
References
Knoechel, B. et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat. Genet. 46, 364–370 (2014).
Sequist, L.V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
Sharma, S.V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010).
Yao, Z. et al. TGF-b IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl. Acad. Sci. USA 107, 15535–15540 (2010).
Weng A.P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269–271 (2004).
Palomero, T. et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 13, 1203–1210 (2007).
Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524–528 (2011).
Ethics declarations
Competing interests
C.R.V. is a consultant for Tensha Therapeutics. The other authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Cancer therapy resistance: chasing epigenetics. Nat Med 20, 340–341 (2014). https://doi.org/10.1038/nm.3528
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3528
- Springer Nature America, Inc.
This article is cited by
-
A nanoparticulate pre-chemosensitizer for efficacious chemotherapy of multidrug resistant breast cancer
Scientific Reports (2016)